Stephens assumed coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday, MarketBeat.com reports. The firm issued an overweight rating and a $140.00 price objective on the biotechnology company’s stock. Other equities analysts have also issued research reports about the company. SVB Leerink raised Blueprint Medicines from an underperform […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 4,540,000 shares, a growth of 6.8% from the April 15th total of 4,250,000 shares. Based on an average daily volume of 830,500 shares, […]
Blueprint Medicines Co (NASDAQ:BPMC) Insider Sells $190,515 92 in Stock dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines (NASDAQ:BPMC) Upgraded to Market Perform at SVB Leerink themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Eagle Asset Management Inc. lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 2.3% in the 3rd quarter, Holdings Channel reports. The fund owned 209,117 shares of the biotechnology company’s stock after acquiring an additional 4,732 shares during the quarter. Eagle Asset Management Inc.’s holdings in Blueprint Medicines were worth $10,502,000 as […]